Q
A
CannaInvestor Magazine: Will the platforms in the United States and internationally, be hemp-derived CBD and/or medical cannabis?
Cannalogue: Our in-house technology is globally scalable and, in the US, we’ll first move into the hemp-derived CBD market. Afterwards, we’ll pursue the medical cannabis market in each state where able. A similar approach will be taken for jurisdictions like the UK and Germany where CBD is legal with subsequent pursuit of the medical cannabis market thereafter.
Q
CannaInvestor Magazine: Why do you think there is market demand in the United States and internationally for your platform?
A
Cannalogue: The market demand stems from the medical benefits of cannabis as well as having a trusted, reliable service.
There are millions of medical cannabis users worldwide and for the first time in history, patients are using it ahead of the traditional evidence and in place of established pharmaceuticals. Plenty of research exists, but more studies with higher quality are emerging all the time. Conditions include chronic pain, arthritis, cancer-induced symptoms, PTSD, anxiety, MS spasticity and more. Our platform brings safe, convenient access while knowing that a physician-led team is curating the products and ensuring quality.